RxDoctor Payments Data

Eric Mathis, DO

Family Medicine · Lawton, OKNPI 1699238105

Payments from drug & device makers

$851in general payments, 2019–2025

Across 56 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$322
  • AstraZeneca$142
  • Pfizer$92
  • AbbVie$70
  • Exact Sciences$63
  • Novo Nordisk$45
  • plus $117 from 4 others

What the payments were for

  • Food & beverage$851100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$851 in reported general payments places this provider in the 60th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$4,439
Medicare patients
64
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide192$204,200
EliquisApixaban202$194,561
OzempicSemaglutide128$147,871
JardianceEmpagliflozin97$114,257
MounjaroTirzepatide93$102,746
Trelegy ElliptaFluticasone/Umeclidin/Vilanter103$71,027
FarxigaDapagliflozin Propanediol46$49,473
JanuviaSitagliptin Phosphate31$29,532
MyrbetriqMirabegron35$28,704
Breo ElliptaFluticasone/Vilanterol58$26,416
XareltoRivaroxaban23$25,946
EntrestoSacubitril/Valsartan17$24,741
RexultiBrexpiprazole12$20,423
Advair HfaFluticasone Propion/Salmeterol42$15,008
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$13,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$322$306,945285 claims
PfizerEliquis$92$194,561202 claims
Novo NordiskOzempic$45$147,871128 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$43$114,670195 claims
AstraZenecaFarxiga, Symbicort$142$55,48365 claims
AbbVieSynthroid$70$5,20498 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Lawton

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →